Skip to content

3D Ultra Sound for Resection of Brain Tumors

Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02150564
Acronym
SonoRCT
Enrollment
72
Registered
2014-05-30
Start date
2014-03-31
Completion date
2019-06-30
Last updated
2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Resectable Brain Tumors

Keywords

Malignant gliomas, Sono RCT

Brief summary

Phase 3 randomized open labeled trials will evaluate the 3 D navigable ultrasound (SonoWand) in improving the extent of resection in intra-axial brain tumors. All patients will undergo resective surgery. In the experimental arm, a navigable 3 D ultrasound will be used. In the standard arm, only navigation will be used. This study will help in assessing the usefulness sononavigation in improving radicality of resection in malignant gliomas and also to access the accuracy of SonoWand in predicting residue (histopathological correlation).

Detailed description

Routine presurgical evaluation of all patients will be conducted. The preoperative use of steroids, antiepileptics and other medications would be as per standard procedure and would be documented. In addition detailed MRI evaluation will be performed (including contrast enhanced MRI study, diffusion MRI, perfusion MR, MR spectroscopy, dynamic-contrast-enhanced MRI for permeability studies, as well as functional MRI, and tractography if required) not more than 1 week prior to the date of surgery. Navigation specific MR sequences would be performed in all patients (both arms).

Interventions

DEVICESonowand

Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure

PROCEDURENavigation

Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.

Sponsors

Tata Memorial Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. All radiologically-suspected, previously untreated, supratentorial malignant gliomas being considered for debulking surgery. 2. Adults (above 18 years) 3. Eligible for surgical therapy (craniotomy not stereotactic biopsy ) 4. Resectability : A lesion would be considered resectable if the surgeons feel that all the radiologically imaged lesion can be removed (with reasonable certainty). Only deemed resectable lesions will be included

Exclusion criteria

1. Unfit for GA 2. Unwilling for the study 3. Unresectable lesion

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients where Gross total resection (GTR) achievedPost operative within 72 hrs.Measure: Volumetric MRI - residual tumor (in cc)

Secondary

MeasureTime frameDescription
Accuracy of USPost operative within 72 hroursMeasure: Sensitivity, Specificity, PPV, NPV

Other

MeasureTime frameDescription
Further resection promptedIntraoperativeWhether use of the SonoWand prompted a further resection after the surgeon thought it was complete (Unanticipated residue)
Survival3 yearsoverall and Progression-free

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026